Powered By
ESTROGEN RECEPTOR ANTAGONIST
Inluriyo (imlunestrant) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat some adults with certain types of metastatic breast cancer.
Inluriyo is a type of medication called an estrogen receptor antagonist. It attaches to estrogen receptor alpha and can help break down this receptor in cancer cells. This reduces estrogen-driven signals that help some breast cancer cells grow and divide.
In breast cancer, this may help slow cancer growth. Doctors prescribe Inluriyo to treat adults with estrogen receptor-positive (ER-positive), human epidermal growth factor receptor 2-negative (HER2-negative), advanced or metastatic breast cancer with an ESR1 mutation after at least 1 endocrine therapy has stopped working.
Doctors prescribe Inluriyo when adults have ER-positive, HER2-negative, advanced or metastatic breast cancer with an ESR1 mutation after at least one endocrine therapy has stopped working.
Inluriyo is given as a tablet by mouth, usually once a day. It should be taken on an empty stomach, either two hours before food or one hour after food, at about the same time each day. Do not split, crush, or chew tablets; they should be swallowed whole.
Treatment usually continues until the cancer gets worse or side effects become unacceptable or intolerable.
The recommended dose of Inluriyo for breast cancer is 400 milligrams by mouth once daily.
Doctors may pause treatment, lower the dose, or stop treatment if side effects are serious or too hard to manage.
This information is based on the prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical trials of Inluriyo used alone for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy, the most common side effects were those reported in at least 10 percent of people taking Inluriyo.
These side effects include:
Inluriyo can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Eli Lilly, the manufacturer of Inluriyo, offers the Inluriyo Savings Card Program. Eligible people with commercial insurance may pay as little as $0 for a one-month prescription fill of Inluriyo. People enrolled in government-funded healthcare programs are not eligible.
The Inluriyo Savings Card Program also offers help through Lilly Support Services, including a benefits investigation to help eligible enrolled people understand coverage options, locate the appropriate specialty pharmacy, and identify their lowest possible out-of-pocket cost. The program also provides guidance through the specialty pharmacy process and an overview of potential savings opportunities.
To learn more, visit the Inluriyo savings and support website, call 844-583-3550, or call Lilly Support Services at 800-LillyRx (800-545-5979).
Before starting Inluriyo, your doctor will test for ESR1 mutations in a plasma sample. This helps your doctor know if Inluriyo is right for you. Your doctor will also check for pregnancy if you can become pregnant.
Tell your doctor about all medications you take, including prescription drugs, over-the-counter medicines, and supplements.
If you miss a dose by six hours or more, or if you vomit after taking it, skip that dose and take your next dose the following day at your regular time.
Inluriyo can harm your baby if taken during pregnancy. Females who can become pregnant should use effective birth control during treatment and for one week after the last dose. Males with female partners who can become pregnant should use effective birth control during treatment and for one week after the last dose.
Inluriyo may affect fertility in females and males. Do not breastfeed during treatment with Inluriyo and for one week after the last dose.
These answers are fact-checked by our editorial staff.
How effective is Inluriyo?
In a study of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, people taking Inluriyo had a median progression-free survival of 5.5 months. This means half of the people lived this long without their cancer getting worse or dying. People taking fulvestrant or exemestane had a median progression-free survival of 3.8 months.
Among people with measurable disease, the objective response rate was 14.3 percent with Inluriyo. It was 7.7 percent with fulvestrant or exemestane. Overall survival results were not able to be analyzed at the time of the analysis, but may be available in the future when more time has passed.
What tests or monitoring are needed with Inluriyo for breast cancer?
People taking Inluriyo may need liver blood tests, because AST and ALT can increase during treatment and monitoring is recommended as clinically indicated. Lipid monitoring is also recommended before starting treatment and periodically during treatment, because cholesterol and triglycerides can increase while taking Inluriyo. Before starting treatment, females of reproductive potential should have pregnancy status checked.
On MyBCTeam, people share their experiences with breast cancer, get advice, and find support from others who understand.
Learn more about Inluriyo and breast cancer care:
Become a member to get even more
Join
Your Privacy Choices
